Drug intelligence / Profile preview

Kamillin Konzentrat Robugen

Development stage
Unknown
Lead developer
Robugen
Administration
Oral, Topical, Inhalation
01

Overview

Kamillin Konzentrat Robugen is a traditional herbal medicinal product containing a highly concentrated extract of chamomile flowers (Matricaria recutita). Developed and marketed by Robugen GmbH, it is produced from specially bred chamomile varieties and contains 95.8 g of extract per 100 ml of solution. The extract is rich in bioactive constituents such as levomenol ((-)-α-bisabolol), apigenin, apigenin-glucoside, and matricin, which contribute to its anti-inflammatory, antispasmodic, and antimicrobial properties. It is indicated for the relief of mild gastrointestinal cramps (oral use), cold symptoms (steam inhalation), and inflammatory or irritated skin and mucous membrane conditions, including the oral cavity, gums, and genital areas (topical use).

Brand names
KAMILLIN KONZENTRAT ROBUGEN
Other names
Kamillin KonzentratKamillenblütenextraktchamomile flower extractMatricaria recutita extract
02

Targets

LOX (Arachidonate lipoxygenase)FOS (Activator Protein 1)COX

Beyond the preview

Go deeper on Kamillin Konzentrat Robugen.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Kamillin Konzentrat Robugen.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call